The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and represent the first new class of pain medications in 20 years—and the first non-opioid painkiller since that class first appeared on the market in the 1980s.
The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday.
The drug, Journavx, from Vertex Pharmaceuticals, reduced pain after surgery in clinical trials. Experts hope it can lead to fewer opioid prescriptions.
The U.S. Food and Drug Administration wants to put nutrition information front and center on food products to give consumers an easier way to identify nutrients linked to chronic diseases. The FDA announced its plans to push for a rule that would require food manufacturers to include a front-of-package nutrition label on most packaged food products.
The FDA is overhauling food labels to redefine "'healthy," focusing on redefining terms and introducing new front-of-package labels.
U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated with opioids.
Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, potentially limiting patients’ ability to access it.
It was given to people who had acute surgical pain from either abdominoplasty, also known as a tummy tuck, or bunion surgery.
Over 35 years after the first study linking the artificial food dye Red 3 to thyroid cancer in rats was published, the U.S. is beginning to phase it out of foods and drugs.
The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often follows surgery or injuries. It’s the first new pharmaceutical approach to treating pain in more than 20 years,
The US Food and Drug Administration signed off Thursday on the first new type of pain reliever to be approved in more than two decades.The<a class="excerpt-read-more" href=" More